ANTX AN2 Therapeutics, Inc. Common Stock

XNAS 3.63 Delayed
Find condors

Stock quote, options chain, IV rank, technicals, AI analysis, and institutional ownership. Iron condor setups Fibonacci levels Insider trading

Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.

ANTX $3.63 —
Key stats
$3.63
52-Week Range
$1.00 – $7.19
YTD
+227.03%
Straddle Price
$4.90
P/C Vol Ratio
0.02
Market Cap
$0.1B
Open
$3.55
Day Range
$3.50 – $3.70
Volume
196,183
Prev Close
$3.55
Fair Value
+50.0% vs price

A blended fair-value estimate combining up to six valuation methods. Each method is weighted by how well it fits the company — DCF down-weights for unprofitable names; DDM only fires for steady dividend payers; comparables down-weight when peer multiples disagree.

  • DCF (quality-aware) — projects free cash flow with a horizon that scales to business quality. True compounders (quality 6/6) get 10 years explicit + 10 years fade before terminal; cyclical/struggling names (quality 0-1) get a 5-year terminal cliff. Quality is scored from ROE, gross margin, growth, FCF margin, debt load, and FCF consistency — the same factors that drive market premium for compounders.
  • Market-Implied Growth (in Model Inputs) — reverse-DCF that answers "what growth rate is the market pricing in?". Lets you sanity-check the deviation: if implied growth is plausible for the business, the model's bearish flag may be wrong; if implausible, the market may be over-extrapolating.
  • DDM (Gordon Growth Dividend Model) — values the stream of future dividends. Only used when trailing yield ≥ 2% and dividend payments are stable — below that the dividend is a token payout and Gordon (which values only the dividend stream) systematically underprices growth names, so those route to DCF + comparables + market anchor instead.
  • P/E, EV/EBITDA, P/B, P/S — applies the peer-group median multiple to this company's per-share metric. Peers come from the same set as the "Related symbols" card. Earnings/sales metrics are forward-tilted by the company's recent revenue growth (capped at 25%) so they're comparable to peers' growth-embedded multiples — mimics how analysts use NTM rather than TTM. Per-multiple weights are biased by company quality (e.g. P/B down-weighted for asset-light tech).
  • Market Anchor (SMA50) — the 50-day moving average, weighted by recent trading-range stability (tighter Bollinger bands → higher weight). Captures information fundamentals miss (forward consensus, sentiment, supply/demand) — but only when recent trading is steady enough that the market has converged on a view. During wild breakouts or breakdowns the anchor's weight collapses.
  • Options Expected (B-L 30d) — the risk-neutral expected stock price at 30-day options expiration, derived from the full implied-volatility surface via Breeden-Litzenberger (second derivative of call price wrt strike → implied PDF, then E[S_T]). Forward-looking, captures all options-implied information (smile, skew, term structure) in one number. Weighted by chain liquidity. SP500-only at present (pre-computed daily). Backtest evidence: adds modest alpha across most bucket × holding combos.
  • Blended value — weighted average. Confidence reflects how many methods fired and how tight peer dispersion is.
  • Deviation pill — green when blended FV ≥ 10% above current price (undervalued); red when ≥ 10% below; grey otherwise.
10-yr Treasury (rf)5.13%
Beta vs SPY0.93
Cost of Equity (CAPM)9.78% (VRP-adj)
WACC9.79%
Volatility Risk Premium+134.5pp (IV − HV30)
Effective Tax Rate21.0%
Rev. Growth (YoY, DCF input)+3.0%
DCF Horizon5 years explicit + fade
Forward Tilt (NTM/TTM)×1.03 (applied to P/E, EV/EBITDA, P/S)
Free Cash Flow (TTM)$-0.0B
Return on Equity (TTM)-47.8%
Book / Price61.3% — banking bias active (P/B is primary)
Debt / Equity0.00
Quality Score1/6 — cyclical/struggling (5y DCF)
SMA 50$5.06 (Market Anchor value)
SMA 20 / Bollinger Mid$4.38
Bollinger Width / SMA201739.5% (drives anchor stability)
Net Debt$-0.0B
Market Cap$0B
Peers used for multiples: ABT, NVS, PFE (SIC-code peers; ETF co-membership was sector-incoherent)
Blended Fair Value
$7.56
Deviation
+50.0%
MethodImplied PriceWeightDetail
DCF n/a 0%
DDM (Gordon) n/a 0%
Peer P/E n/a 0% median 40.0× · 3 peers
Peer EV/EBITDA n/a 0% median 19.0× · 3 peers
Peer P/B $7.56 100% median 3.5× · 3 peers
Peer P/S n/a 0% median 3.8× · 3 peers
Market Anchor (SMA50) $5.06 0% stability 0% (BB-width)
Options Expected (B-L 30d) $3.29 0% 6 strikes · skew +0.59
As of 2026-10-26 · updated
About
Industry (SIC)
PHARMACEUTICAL PREPARATIONS (2834) · industry map
Exchange
XNAS
Market Cap
$0.1B
Employees
21
List Date
2022-03-25
CIK
0001880438
Next Earnings
2026-11-11 (Pre-Market)
Headquarters
Menlo Park, CA
Homepage
https://www.an2therapeutics.com

AN2 Therapeutics Inc is a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics derived from its boron chemistry platform. The company has a pipeline of boron-based compounds in development for Chagas disease, non-tuberculous mycobacterial (NTM) and melioidosis, along with early-stage programs focused on targets in infectious diseases and oncology. Product candidate AN2-502998 Epetraborole.

Summary
—
composite
—
No summary data available for this symbol yet.

Each spoke is this symbol's rank within its sector (0–100; the dotted ring marks the sector median at 50). Higher is more constructive for a long. One spoke — News sentiment — is an absolute reading, not a sector rank. Grayed spokes have no data. A fuller shape is a summary, not a recommendation.

Chart
Seasonality
'22'23'24'25'26Avg
Jan--25.10%-2.87%-17.99%1.80%1.51%
Feb---19.54%-85.06%4.59%-1.79%-25.45%
Mar-2.14%-13.42%8.33%21.97%216.67%46.28%
Apr-1.01%-20.79%-36.17%-10.14%31.88%-7.25%
May-10.45%-28.26%-17.08%-14.52%-7.48%-15.56%
Jun-48.37%42.38%2.38%0.00%14.96%2.27%
Jul4.90%-2.87%19.72%0.95%12.16%6.97%
Aug125.23%83.41%-55.69%3.77%-0.54%31.24%
Sep19.37%5.44%-2.73%10.43%-2.92%5.92%
Oct-22.05%-7.03%2.86%-4.65%-35.41%*-13.26%
Nov-26.75%21.26%54.63%-5.22%--10.98%
Dec-4.22%22.04%-13.75%8.57%--3.16%
Total-30.92%82.22%-93.97%-8.79%210.64%31.84%
Technical Indicators

Quick-reference for reading the values below. Indicators combine to confirm a view — no single one is a trade signal on its own.

Trend Indicators
  • SMA 20 / 50 / 200 — price above = uptrend, below = downtrend. SMA 50 crossing SMA 200 is the golden/death cross.
  • EMA 12 / 26 — faster-reacting averages; 12 above 26 is short-term bullish.
  • MACD — bullish when MACD > signal (green badge), bearish when below. Divergence from price often precedes reversals.
  • ADX (14) — trend strength regardless of direction. <20 range, 20–25 weak trend, 25–50 trend, >50 strong trend.
  • +DI / −DI — +DI > −DI favors bulls; the reverse favors bears. Read alongside ADX.
Momentum Oscillators
  • RSI (14) — <30 oversold, >70 overbought. 40–60 is neutral; trending names can stay extreme.
  • Stochastic %K / %D — <20 oversold, >80 overbought. %K crossing %D is an early momentum signal.
  • Williams %R — inverted scale: <−80 oversold, >−20 overbought.

Oscillators work best in range-bound markets; in strong trends they give premature reversal signals.

Volume & Volatility
  • Bollinger Bands — price at upper band = overbought, lower = oversold. Narrow bands (squeeze) often precede expansion.
  • OBV — cumulative volume; rising OBV confirms uptrend, falling OBV confirms downtrend. Divergence from price is a warning.
  • Vol SMA 20 / Vol ROC — today's volume vs. 20-day average. Positive ROC with price move = conviction.
  • ATR / True Range — average daily $ move; sizing and stop-loss reference.
  • HV 20 / 30 / 60 — realized (historical) volatility. Compare to IV on the options cards: IV > HV = rich premium.

Confluence matters: trend + momentum + volume agreeing carries far more weight than any single indicator. For how these feed the spread scanner score, see the algorithm docs →

Trend Indicators

SMA 20: $4.31
SMA 50: $5.01
SMA 200: $4.01
Current: $3.63
EMA 12: $3.82
EMA 26: $4.28
MACD: -0.4634 | Signal: -0.0299
BEARISH
ADX (14): 32.41
TREND
+DI: 15.40
−DI: 32.12

Momentum Oscillators

RSI (14): 32.52
NEUTRAL
Stoch %K: 17.72
Stoch %D: 15.61
Williams %R: -77.30

Volume & Volatility

BB Upper: $5.97
BB Lower: $2.64
NEUTRAL
OBV: 75,982,345
Vol SMA 20: 303,078
Vol ROC: -34.34%
ATR: $0.33
True Range: $0.20
HV 20: 88.4%
HV 30: 77.5%
HV 60: 67.7%

Data Summary

Data Points: 500
Last Updated:
Date Range: 2024-10-28T00:00:00 – 2026-10-26T00:00:00
AI Analysis

LLM Stock Analysis Report: ANTX

Executive Summary

Overall Assessment: NEUTRAL (Confidence Level: 6/10)

Key Drivers:

  • Technical signals indicate oversold conditions, suggesting potential for a short-term rebound
  • Low volatility and low beta suggest reduced risk profile
  • Lack of recent news headlines limits sentiment impact

Primary Risks:

  • No significant catalysts or earnings dates in the near term
  • Continued low volatility may not provide enough momentum for price increases

Investment Thesis: ANTX's technical indicators suggest an oversold condition, which could lead to a short-term rebound. However, the lack of recent news headlines and earnings dates limits sentiment impact, making it challenging to determine the stock's medium- to long-term direction.

Recent News Sentiment Impact: None (no recent news available)

Technical Analysis

Trend Direction: Short-term: Bearish (SMA 20 > current price), Medium-term: Neutral (SMA 50 and SMA 200 in alignment), Long-term: Bullish (ema 12 and ema 26 aligned above SMA 200)

Support/Resistance Levels:

  • Key support level: $1.19 (current price)
  • Resistance levels:
    • Short-term: $1.27 (SMA 20)
    • Medium-term: $1.34 (Upper Bollinger Band)
  • Squeeze area: Not present

Momentum Signals:

  • RSI interpretation: Neutral (41.61), oversold territory, potential buy signal
  • MACD signal: Bullish (Histogram >0.01), suggests upward momentum
  • Bollinger Bands position: Oversold (price touching lower band)

Volume Analysis:

  • Volume SMA 20: 45614.90, indicating moderate volume levels
  • On-Balance Volume (OBV): 2616092.00, suggesting accumulation
  • Volume Rate of Change: -45.43%, indicating a decrease in volume

News & Sentiment Analysis

Recent Headlines Summary: None (no recent news available)

Sentiment Assessment: Neutral

Catalyst Identification: None

Market Narrative: Technical signals dominate the analysis, with no significant news headlines impacting sentiment.

Risk & Volatility Assessment

Beta Interpretation: Low risk profile (beta 0.62 vs SPY), indicating reduced volatility relative to the market

Volatility Regime: Low volatility regime, suggesting a stable price environment

Options Market Signals:

  • IV rank: Not available
  • Put/call ratios: Not available
  • Unusual activity: None

Downside Protection: Support level at $1.19, potential stop-loss levels based on SMA 20 and Upper Bollinger Band.

Market Context & Positioning

Sector Performance: Neutral (sector performance not provided)

Institutional Activity: Moderate institutional interest signals (OBV accumulation)

Correlation Analysis: Low correlation with market (R-squared not provided)

Relative Valuation: Position within trading range, suggesting potential for a short-term rebound.

Key Levels & Action Items

  • Critical price levels:
    • Support: $1.19
    • Resistance: $1.27 and $1.34
  • Breakout/Breakdown Levels:
    • Short-term: $1.27 (SMA 20)
    • Medium-term: $1.34 (Upper Bollinger Band)
  • Time-Sensitive Catalysts: None
  • Risk Management: Monitor SMA 20 and Upper Bollinger Band for potential stop-loss levels.

Please note that this analysis is based on the provided data, and further research may be necessary to confirm or modify the findings.

Generated
Earnings History
1 of 1 under expected move
Avg Expected Move
82.91%
Avg Actual Move
0.68%
Each row pairs the pre-earnings straddle-implied expected move with the realized close-to-close move. Sorted oldest first.
Earnings Date Timing Expected Move Actual Move Ratio Outcome
2026-08-11 Pre-Market 82.91% 0.68% 0.01x Within

Earnings calendar: this week’s reports with expected vs actual moves →

ANTX Options Activity & IV Rank

Volatility Metrics

Current IV: —
7-DTE IV: —
Expected Move: $4.90
7-DTE Move: $4.90
Days to Exp: 25 (2026-11-20)

Options Flow

Call Volume: 41
Put Volume: 1
P/C Volume: 0.024
BULLISH
Call OI: 2
Put OI: 0
P/C OI: —
Total OI: 2

ATM Options Pricing

ATM Call: $2.45
ATM Put: $2.45
Call %: 67.5%
Put %: 67.5%

Chain Summary

Chain Volume: 185
Chain OI: 119
Last Updated: 10/26/2026
Spread Scanner GPU
Full Algorithm Docs ↗

Each spread is ranked by a composite score built in three stages. Full documentation →

Stage 1 — Base Score (GPU scanner)

score = P(profit) × (credit / spread_width)
P(profit) from short leg delta (1 − |delta|), penalised above 85%. Credit uses mid-price to handle illiquid chains fairly.

Stage 2 — Skew Adjustment (±25% cap)

RR and BF (30-delta) from the persisted per-symbol skew snapshot — wing strikes picked by real greeks.delta, not a moneyness proxy. Put skew boosts bull puts, penalises bear calls. High butterfly boosts iron condors. Calendars are skew-neutral.

Stage 3 — Technical Overlay (±50% cap, 5 groups)
Group 1 · Directional Bias (±0.25)
  • RSI <40 bullish / >60 bearish
  • MACD crossover + histogram trend
  • Price vs SMA 50 & SMA 200
Group 2 · Momentum (±0.10)
  • Stochastic %K <20 / >80
  • Williams %R <−80 / >−20
Group 3 · Volatility (up to −0.25 / +0.15)
  • Blended ATR + straddle expected-move penalty
  • Bollinger Band signal (+ counter-trend penalty)
  • BB width — vol contraction boost for ICs
Group 4 · IV Regime (±0.15)
  • IV rank ≥ 75 → strong boost for credit spreads
  • IV rank < 25 → penalty (selling cheap vol)
Group 5 · Liquidity (penalty up to −0.10)
  • Min open interest across all legs
  • OI < 100 → −0.10 · OI < 500 → −0.05

score = base_score × skew_multiplier × tech_multiplier
Both multipliers are shown per spread. Beta is informational only — ATR already captures realized vol. Full algorithm documentation →

Enter a ticker to scan for optimal spread opportunities.

Evaluates all bull put, bear call, iron condor, and calendar spread combinations using GPU-accelerated analysis.

Skew (Wing IV − ATM IV)
DTE:
Wing Δ:
Metric:
Wing vs ATM
IV(put wing) − IV(ATM), in vol points

How much the OTM put trades above (or below) the at-the-money strike. Measures the height of the put-side tail relative to ATM — i.e. how expensive crash insurance is on this name.

  • Positive (typical) — wing IV > ATM IV. Standard equity put skew: portfolios bid up crash protection, so OTM puts trade richer than ATM.
  • Near zero or negative (unusual) — wing IV ≤ ATM IV. Flat or inverted put side. Common when there's no fear demand, in tightly mean-reverting names, or right after an earnings catalyst clears.
  • Percentile vs own 3-yr history: high = wings rich (good time to sell wing premium); low = wings cheap (good time to buy protection).
  • Not directional — high or low wings don't predict up or down moves. It's a price tag on tail insurance, not a forecast.
Risk Reversal
IV(call wing) − IV(put wing), equal delta on each side

Which side of the smile is the market paying up for? Measures the tilt of the surface — call skew vs put skew at matched deltas.

  • Negative (typical) — puts richer than calls. Standard equity behavior: hedging demand makes puts carry a premium. Most large-caps sit in the −1 to −5 vol-point range.
  • Strongly negative (< −5 pts) — heavy downside hedging, elevated fear, or an upcoming catalyst (earnings, FDA, macro event). Worth flagging.
  • Positive — calls richer than puts. Unusual for equities; signals bullish momentum, short-squeeze positioning, or takeover/M&A speculation.
  • Near zero — symmetric surface. Market sees roughly equal up/down risk. Rare for large-caps; more common in commodities and FX.
Reading them together

Wing-vs-ATM tells you how expensive the tails are. Risk Reversal tells you which side is favored. Combined:

  • High wing percentile + deeply negative RR → strong put bid; stress or major event priced in. Owning protection costs a premium; selling put premium is dangerous.
  • Low wing percentile + near-zero RR → complacency; insurance cheap and balanced. Good environment to add cheap downside hedges.
  • Positive RR + elevated wings → call-side fear-of-missing-out; common in squeeze setups. Upside calls expensive, downside puts not bid.
14 DTE / 10d —
— pts EXTREME
as of Oct 26 · No data
30 DTE / 10d —
— pts EXTREME
as of Oct 26 · ATM 465.9% / Wing —

Percentile is the rank of today's reading within ~3 years of this symbol's own history. High percentile = wings are rich relative to history; not a directional signal. Skew is read off the chain in real time, not from CBOE SKEW.

Volatility Surface

Enter a ticker to render the implied volatility surface.

Volatility Smile

Enter a ticker to render the implied volatility smile.

IV Rank (7 DTE)
IV Rank (30 DTE)
Straddle Price (30 DTE)$4.90Oct 26
Beta Analysis

Risk Metrics

Beta: 0.5572
Alpha: 175.81%
Correlation: 0.0531
R-Squared: 0.3%
Stock Volatility: 133.7%
Market Volatility: 12.7%

Analysis Details

Benchmark: SPY
Data Points: 251
Period: 252 trading days
Interpretation:
Low volatility - stock moves less than market
Beta & Alpha Over Time
Notable investors who own ANTX
3 of 37 tracked investors
InvestorValueShare of their portfolioRankQ/Q sharesSource
Millennium Management Hedge fund
Izzy Englander
$11.2M
0.01%
#1500 of 3716+4.3%13F
Citadel Hedge fund
Ken Griffin
$4.6M
0.00%
#2168 of 6285+513.2%13F
Renaissance Technologies Hedge fund
Jim Simons
$628K
0.00%
#2514 of 3138-34.8%13F

Hedge funds, activists, holding companies and family offices we track, from their latest 13F (quarter-end value) and Form 4 filings in the last 3 years. Family offices · all institutions

ANTX Institutional Ownership (13F)

Latest filings — 2026-09-30
Diluted shares outstanding: 34,864,410 (as of 2026-06-30)

Institutional managers with $100M+ AUM file Form 13F-HR quarterly, due 45 days after quarter end. Holdings are reported gross at quarter-end market value — they are a snapshot, not a real-time position.

  • Shares — long equity positions in this name, aggregated across share classes.
  • Calls / Puts — notional value of long call / put exposure where this ticker is the underlying.
  • % of Float — holder's reported shares divided by the latest diluted shares outstanding. Sums above 100% indicate large custodian / prime broker positions where the same shares are reported by multiple filers.
  • Custodian badge — filers with more than 5,000 holdings are typically broker-dealers / custodians reporting customer-held shares, not active managers.

Each filer is counted once at its latest 13F-HR filing. New filings are ingested on a weekly cadence.

71 filers26,031,923 shares$122.00M value74.67% of float
# Filer Shares Value % of Total % of Float Period
1 Vivo Capital, LLC 3,153,640 $15.26M 12.51% 9.05% 2026-06-30
2 Commodore Capital LP 2,933,680 $14.20M 11.64% 8.41% 2026-06-30
3 Millennium Management LLC Custodian 2,318,692 $11.22M 9.20% 6.65% 2026-06-30
4 BlackRock, Inc. Custodian 1,665,494 $8.06M 6.61% 4.78% 2026-06-30
5 Spruce Street Capital LP 1,661,073 $8.04M 6.59% 4.76% 2026-06-30
6 Almitas Capital LLC 1,469,129 $7.11M 5.83% 4.21% 2026-06-30
7 Vanguard Capital Management LLC 1,238,705 $6.00M 4.91% 3.55% 2026-06-30
8 ADAGE CAPITAL PARTNERS GP, L.L.C. 1,000,000 $4.84M 3.97% 2.87% 2026-06-30
9 Citadel Advisors LLC Custodian 951,997 $4.61M 3.78% 2.73% 2026-06-30
10 Boxer Capital Management, LLC 749,035 $3.63M 2.97% 2.15% 2026-06-30
11 Geode Capital Management, LLC Custodian 697,806 $3.38M 2.77% 2.00% 2026-06-30
12 SummitTX Capital, L.P. 597,453 $2.89M 2.37% 1.71% 2026-06-30
13 Balyasny Asset Management L.P. 556,027 $2.69M 2.21% 1.59% 2026-06-30
14 Stonepine Capital Management, LLC 551,692 $2.67M 2.19% 1.58% 2026-06-30
15 Ameriprise Financial, Inc. Custodian 537,064 $2.60M 2.13% 1.54% 2026-06-30
16 Sio Capital Management, LLC 529,933 $2.56M 2.10% 1.52% 2026-06-30
17 Ally Bridge Group (NY) LLC 526,315 $2.55M 2.09% 1.51% 2026-06-30
18 Prosight Management, LP 474,638 $2.30M 1.88% 1.36% 2026-06-30
19 Woodline Partners LP 459,805 $2.23M 1.82% 1.32% 2026-06-30
20 Aldebaran Capital, LLC 367,435 $1.78M 1.46% 1.05% 2026-06-30
21 State Street Corp 311,602 $1.51M 1.24% 0.89% 2026-06-30
22 Vanguard Group Inc Custodian 1,080,070 $1.23M 1.01% 3.10% 2025-12-31
23 Northern Trust Corp Custodian 214,921 $1.04M 0.85% 0.62% 2026-06-30
24 Seven Fleet Capital Management LP 208,946 $1.01M 0.83% 0.60% 2026-06-30
25 Vanguard Fiduciary Trust Co 196,920 $953.09K 0.78% 0.56% 2026-06-30
# Filer Notional Value % of Total Period
# Filer Notional Value % of Total Period

ANTX Insider Trading (Form 4)

Latest: 2026-10-13
Form 4 filings — insider beneficial-ownership changes by officers, directors, and 10%+ holders. Filed within 2 business days of transaction.
Filed Reporter Role Action Shares Avg Price Net $ Link
2026-10-13 Patricia A. Martin Director Award (A) +389 — EDGAR
2026-10-13 Gilbert Lynn Marks Director Award (A) +2,283 — EDGAR
2026-10-13 Kabeer Aziz Director Award (A) +2,465 — EDGAR
2026-09-16 Cameron C. Trenor III Chief Medical Officer Award (A) +116,667 — EDGAR
2026-09-11 Robin Shane Readnour Director Sell (S) −1,108 $6.02 -$6.7K EDGAR
2026-09-08 Robin Shane Readnour Director Sell (S) −16,119 $6.04 -$97.3K EDGAR
2026-09-04 Sarah Joanne Williams Principal Accounting Officer Sell (S) −272 $5.53 -$1.5K EDGAR
2026-09-02 Margaret M FitzPatrick Director Buy (P) +2,098 $5.53 $11.6K EDGAR
2026-08-19 Robin Shane Readnour Director Sell (S) −35,402 $6.01 -$212.7K EDGAR
2026-08-14 Joseph S Zakrzewski Director Gift (G) −405,880 — EDGAR
2026-07-10 Gilbert Lynn Marks Director Award (A) +2,789 — EDGAR
2026-07-10 Joshua M Eizen See Remarks Sell (S) −5,945 $4.17 -$24.8K EDGAR
2026-07-10 Patricia A. Martin Director Award (A) +766 — EDGAR
2026-07-10 Kabeer Aziz Director Award (A) +2,852 — EDGAR
2026-06-02 Sarah Joanne Williams Principal Accounting Officer Sell (S) −265 $4.43 -$1.2K EDGAR
Codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (described in filing footnote — typically 401(k), trust, inheritance) · W = will/inheritance. Only P / S codes carry directional signal.

ANTX Insider Holdings

14 insiders · @ $3.63
Officers, directors, and 10%+ owners who have filed a Form 4 in the past two years, ranked by current disclosed exposure (shares × today's price). Shares are direct + indirect (via trusts / LLCs / spouse). Excludes unvested RSU and option grants — those aren't beneficially owned until vest.
# Insider Role Shares Disclosed Exposure Lifetime OM Net Filings Last Filed
1 Braden Michael Leonard 10%+ Owner 3,017,432 $10.95M -$1.53M 3 2025-06-16
2 Kabeer Aziz Director 2,057,529 $7.47M -$1.48M 23 2026-10-13
3 Eric Easom Chief Executive Officer 1,434,396 $5.21M -$1.44M 19 2026-03-23
4 Robin Shane Readnour Director 633,842 $2.30M $2.28M 16 2026-09-11
5 Joshua M Eizen See Remarks 206,554 $749.8K -$65.9K 13 2026-07-10
6 Joseph S Zakrzewski Director 145,538 $528.3K -$1.88M 13 2026-08-14
7 Sanjay Chanda Chief Development Officer 118,823 $431.3K -$13.3K 9 2026-03-23
8 Lucy Day Chief Financial Officer 118,363 $429.7K -$12.8K 9 2026-03-23
9 Cameron C. Trenor III Chief Medical Officer 116,667 $423.5K $0 1 2026-09-16
10 Gilbert Lynn Marks Director 84,156 $305.5K $0 14 2026-10-13
Lifetime OM Net = signed sum of open-market buys (P) and sells (S) over their career; excludes grants, tax withholdings, and dispositions to issuer. A large negative number is normal for long-tenured executives — they've sold compensation grants over many years.

ANTX Board & Officers

As of SEC filings through Oct 13, 2026

Directors 9

Officers 7

Changes in the last 10 years (43)
Aug 24, 2026Cameron C. Trenor III became Chief Medical Officer
Jan 26, 2026Sarah Joanne Williams became Principal Accounting Officer
Jun 16, 2025Braden Michael Leonard reported in an SEC filing no longer being a 10% owner
Nov 5, 2024Joshua M Eizen listed as Chief Operating Officer and Chief Legal Officer (previously Chief Legal Officer) in SEC filings
Nov 4, 2024Stephen David Prior became Chief Strategy Officer
Aug 13, 2024Rajeev M. Shah reported in an SEC filing no longer being a 10% owner
Aug 13, 2024Ra Capital Management, L.p. reported in an SEC filing no longer being a 10% owner
Aug 13, 2024RA Capital Nexus Fund II, L.P. reported in an SEC filing no longer being a 10% owner
Aug 13, 2024RA Capital Healthcare Fund LP reported in an SEC filing no longer being a 10% owner
Aug 13, 2024Peter Kolchinsky reported in an SEC filing no longer being a 10% owner
Aug 9, 2024Braden Michael Leonard became a 10% owner
Jan 18, 2024Kabeer Aziz no longer listed as a 10% owner in SEC filings
Jan 18, 2024Adjuvant Global Health Technology Fund, L.P. reported in an SEC filing no longer being a 10% owner
Jan 18, 2024Adjuvant Global Health Technology Fund DE, L.P. reported in an SEC filing no longer being a 10% owner
Jan 18, 2024Adjuvant Capital Management, LLC reported in an SEC filing no longer being a 10% owner
Jan 18, 2024Adjuvant Capital GP, L.P. reported in an SEC filing no longer being a 10% owner
Sep 1, 2023The company announced the departure of Michael Adrian Nazak as Chief Accounting Officer in an SEC filing
Sep 29, 2022Joshua M Eizen became Chief Legal Officer
May 5, 2022Margaret M FitzPatrick became a director
Mar 31, 2022Kabeer Aziz first listed as a 10% owner in an SEC filing
Not reported recently (2)
  • Kevin Michael Krause · Last reported as Chief Strategy Officer in an SEC filing dated Mar 29, 2024
  • Paul Eckburg · Last reported as Chief Medical Officer in an SEC filing dated Mar 29, 2024
Compiled from SEC filings by the company and its directors and officers. Dates are as stated in those filings. Where no filing says when someone left, we show the last filing that listed them.

ANTX Proposed Insider Sales (Form 144)

Latest: 2026-08-17
Last 30d: 0 filings  ·  Last 90d: 1 filing · $6.1M notice value · 1 unique filer · 100% under 10b5-1 plans

What is Form 144? A notice of intent to sell restricted or control stock under Rule 144. Affiliates (officers, directors, 10%+ owners) and holders of restricted shares must file Form 144 when planning to sell more than 5,000 shares or $50,000 in any 3-month rolling window.

How it relates to Form 4: Form 144 is filed before the trade (up to 90 days in advance); Form 4 is filed within 2 business days after the trade executes. Not every Form 144 results in a sale — the filer may cancel or delay. Look for the corresponding Form 4 on the Insider Activity card to confirm a sale actually happened.

10b5-1 plans: Trades made under a pre-scheduled Rule 10b5-1 plan are not discretionary — they execute automatically on dates set months earlier, regardless of news. High 10b5-1 percentages mean less per-filing signal value, though cumulative selling volume still matters.

"Notice value": Aggregate market value the filer wrote into the Form 144 — i.e. the size of the planned sale, not necessarily the executed dollars. An amended notice (Form 144/A) replaces the original it amends, and cancelled notices are dropped, so neither is double-counted above. A filed value that is clearly inconsistent with the share count at the stock's price (a filer typo) shows as a dash and is left out of the totals.

Source & freshness: Sourced from public Form 144 filings. Refreshed daily; new filings typically appear here the morning after they are filed.

Top 90-day filers: Readnour Robin Shane (1, $6.1M)
Filed Filer Role Shares Notice Value Planned Sale Broker Plan Link
2026-08-17 Readnour Robin Shane Director 1,012,000 $6.08M 2026-08-17 Stifel Nicolaus & Company Inc 10b5-1 EDGAR
2024-08-15 RA Capital Healthcare Fund LP Affiliate 1,699,998 $1.70M 2024-08-15 BTIG, LLC — EDGAR
2024-08-15 RA Capital Nexus Fund II, L.P. Affiliate 299,999 $306.0K 2024-08-15 BTIG, LLC — EDGAR
2024-01-18 Z3 TRUST Director 100,000 $1.91M 2024-01-18 Morgan Stanley Smith Barney LLC … — EDGAR
2024-01-16 Adjuvant Global Health Technology Fund DE, L.P. Shareholder 15,907 $332.1K 2024-01-16 Merrill — EDGAR
2024-01-16 Adjuvant Global Health Technology Fund, L.P. Shareholder 84,093 $1.76M 2024-01-16 Merrill — EDGAR
2024-01-10 MGC VENTURE PARTNERS 2018 ,LP Officer 9,443 $203.3K 2024-01-10 Morgan Stanley Smith Barney LLC … 10b5-1 EDGAR
2024-01-10 MGC VENTURE PARTNERS QP 2018 ,LP Officer 11,033 $237.5K 2024-01-10 Morgan Stanley Smith Barney LLC … 10b5-1 EDGAR
2024-01-02 ERIC EASOM Officer 2,777 $56.9K 2024-01-02 Morgan Stanley Smith Barney LLC … 10b5-1 EDGAR
2024-01-02 KEVIN KRAUSE Officer 10,000 $204.9K 2024-01-02 Morgan Stanley Smith Barney LLC … 10b5-1 EDGAR
Notice value is the aggregate market value the filer states they intend to sell — not a confirmed transaction. Compare to Insider Activity (Form 4) to see which planned sales actually executed. Market-wide feed: Planned sales (Form 144).
ETF Holders
23 ETFs hold ANTX
23 shown · $11.45M total exposure · 0.00% AUM-weighted avg weight
# ETF Provider Weight $ Exposure ETF AUM As Of
1 VTI Vanguard Morningstar Total Stock Market ETF Vanguard 0.00% $4.5M — 2026-09-30
2 IWM iShares Russell 2000 ETF iShares (BlackRock) 0.00% $2.3M $74.6B 2026-10-23
3 VXF Vanguard Extended Market ETF Vanguard 0.00% $1.9M — 2026-09-30
4 VTWO Vanguard Russell 2000 ETF Vanguard 0.00% $814,838 — 2026-09-30
5 IWN iShares Russell 2000 Value ETF iShares (BlackRock) 0.01% $782,708 $13.9B 2026-10-23
6 IWC iShares Micro-Cap ETF iShares (BlackRock) 0.02% $288,768 $1.2B 2026-10-23
7 DFAS Dimensional US Small Cap ETF Dimensional 0.00% $147,279 — 2026-10-23
8 GSSC Goldman Sachs ActiveBeta U.S. Small Cap Equity ETF Goldman 0.01% $145,294 $1.0B 2026-10-23
9 AVSC Avantis U.S. Small Cap Equity ETF Avantis 0.00% $124,722 $3.2B 2026-10-23
10 VTWV Vanguard Russell 2000 Value ETF Vanguard 0.01% $114,572 — 2026-09-30
11 IWO iShares Russell 2000 Growth ETF iShares (BlackRock) 0.00% $105,978 $13.7B 2026-10-23
12 DFMC Dimensional US Micro Cap ETF Dimensional 0.00% $54,840 — 2026-10-23
13 RSSL Global X Russell 2000 ETF Global X 0.00% $46,272 — 2026-10-26
14 VTWG Vanguard Russell 2000 Growth ETF Vanguard 0.00% $17,795 — 2026-09-30
15 VTHR Vanguard Russell 3000 ETF Vanguard 0.00% $15,311 — 2026-09-30
16 DFAC Dimensional US Core Equity 2 ETF Dimensional 0.00% $12,127 — 2026-10-23
17 ITWO ProShares Russell 2000 High Income ETF ProShares 0.00% $5,496 — 2026-10-26
18 URTY ProShares UltraPro Russell2000 ProShares 0.00% $4,211 — 2026-10-26
19 FSEG Fidelity Enhanced Small Cap Growth ETF Fidelity 0.06% $4,210 $7.6M 2026-10-23
20 FSEV Fidelity Enhanced Small Cap Value ETF Fidelity 0.05% $3,685 $7.8M 2026-10-23
21 UWM ProShares Ultra Russell2000 ProShares 0.00% $2,958 — 2026-10-26
22 HDG ProShares Hedge Replication ETF ProShares 0.00% $116 — 2026-10-26
23 RB ProShares Russell 2000 Dynamic Buffer ETF ProShares 0.00% $36 — 2026-10-26
Fundamentals

Quarterly filings sourced from SEC 10-Q / 10-K reports. TTM tiles aggregate the most recent four quarters; bars show the last ~12 quarters oldest → newest.

Metrics
  • Revenue — top-line sales. Look for consistent YoY growth; seasonal businesses need same-quarter comparisons (Q4 '24 vs Q4 '23).
  • Net Income — bottom-line profit after all expenses. Can be volatile from one-time items; red bars = net loss.
  • Diluted EPS — net income per share assuming options/converts are exercised. Direct input to the P/E ratio.
  • Operating Cash Flow — cash generated from core operations, before capex and financing. Harder to manipulate than net income; growing OCF is a quality signal.
How to read the bars
  • Sequential growth — quarter-over-quarter trend. Accelerating bars are a momentum signal.
  • YoY growth — compare to the same quarter a year earlier to remove seasonality.
  • Quality — OCF should roughly track Net Income over time. Large divergence (net income ≫ OCF) flags accruals risk.
  • Margins — scan the bar ratios: Net Income / Revenue tells you margin trend without needing a separate chart.

TTM (trailing-twelve-month) smooths seasonality and is used for the P/E calculation. Filings appear 30–90 days after the period closes.

Trailing P/E
—
TTM Diluted EPS
$-1.07
TTM Revenue
—
TTM Net Income
$-36.28M
TTM Op. Cash Flow
$-30.68M
Quarterly figures (2 quarters)
QuarterPeriod EndRevenueNet IncomeDiluted EPSOp. Cash Flow
Q2 '262026-06-30—$-8.19M$-0.18$-7.00M
Q2 '252025-06-30—$-6.46M$-0.21$-7.60M
Q2 2026 • period ending 2026-06-30 • filed 2026-08-11
Valuation

Ratios derived from TTM financials and the current market price, sampled daily. History chart shows how expensive the stock is today relative to its own recent past.

Price Multiples
  • P/E — price / TTM earnings. Rough market rule: 10–15 value, 15–25 market, >30 growth/premium. Negative when earnings are negative.
  • P/B — price / book value. Useful for financials and asset-heavy names; meaningless for asset-light software.
  • P/S — price / TTM revenue. Useful when earnings are negative or noisy (early-stage growth).
  • EV/EBITDA — capital-structure-neutral. <10 cheap, 10–15 reasonable, >20 rich. Good for comparing across leverage profiles.
  • EV/Sales — like P/S but accounts for debt + cash. Compare within sector.
Profitability & Yields
  • ROE — return on equity. >15% strong, >25% exceptional. Caution: high leverage inflates ROE.
  • ROA — return on assets. Leverage-neutral; >5% solid, >10% exceptional.
  • Div Yield — annual dividend / price. Compare to 10Y Treasury; sustained yield >6% often signals distress.
  • FCF Yield — free cash flow / market cap. >5% is attractive; negative means burning cash.
Balance Sheet
  • Debt/Equity — leverage. <1 conservative, >2 aggressive. Sector-dependent (utilities naturally high, tech low).
  • Current Ratio — short-term liquidity. >1.5 comfortable, <1 raises short-term solvency flags.
Reading the history chart
  • Compare current level to the 3-year band: near the high end = relatively expensive; near the low = relatively cheap.
  • Multiples expanding while earnings are flat = sentiment-driven rally.
  • Multiples compressing while earnings grow = value coming from fundamentals.
P/E
—
P/B
1.67
P/S
—
EV/EBITDA
—
EV/Sales
—
ROE
-47.8%
ROA
-44.4%
Div Yield
0.00%
FCF Yield
-24.24%
Debt/Equity
0.00
Current Ratio
—
Market Cap
$126.56M
as of 2026-10-26
Short Interest & Float

Regulatory short-interest reports publish on a bi-weekly settlement cadence; short-volume is reported daily by the trade-reporting facilities. Float is derived from insider-ownership filings.

Metric definitions
  • Short Interest — total shares currently sold short as of the settlement date. Lags real time by ~8 business days.
  • SI % of Float — short interest / free float. The key crowding metric.
  • Days to Cover — short interest / avg daily volume. How many full trading days it would take shorts to buy back. High DTC + catalyst = squeeze fuel.
  • Short Vol Ratio — today's short-sale volume / total volume. Intraday selling pressure proxy (not the same as short interest).
  • Free Float — shares available for public trading (total shares minus insider / restricted).
  • Float % — free float / shares outstanding. <50% = tightly held, more prone to squeezes.
How to read the signals
  • SI % of Float < 5% — typical, no particular signal.
  • 5–15% — elevated; watch for catalysts (earnings, guidance, macro).
  • 15–30% — heavily shorted; tight-float names in this range have produced notable squeezes historically.
  • >30% — extreme; borrow is likely expensive and squeeze risk is material.
  • Days to Cover > 5 combined with high SI% amplifies squeeze potential.
History chart
  • Trend matters more than level. Rapidly rising short interest often precedes negative catalysts or heavy hedging.
  • A sudden drop in SI after a rally may indicate a squeeze in progress.

Short interest is reported mid-month and end-of-month; short volume is daily.

Short Interest
2.49M
SI % of Float
8.66%
Days to Cover
9.54
Short Vol Ratio
75.5%
Free Float
28.78M
Float %
76.3%
Short interest 2026-09-30 • Short volume 2026-10-26 • Float 2026-08-17